Pharvaris BV (PHVS) - Total Liabilities
Based on the latest financial reports, Pharvaris BV (PHVS) has total liabilities worth $26.66 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharvaris BV - Total Liabilities Trend (2017–2024)
This chart illustrates how Pharvaris BV's total liabilities have evolved over time, based on quarterly financial data. See Pharvaris BV short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Pharvaris BV Competitors by Total Liabilities
The table below lists competitors of Pharvaris BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Systemair AB
ST:SYSR
|
Sweden | Skr3.63 Billion |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
Taiwan | NT$1.05 Billion |
|
ZAI LAB LTD0000006
F:1ZLB
|
Germany | €433.76 Million |
|
Wasu Media Holding Co Ltd
SHE:000156
|
China | CN¥14.28 Billion |
|
Nancal Energy-Saving Tech Co
SHG:603859
|
China | CN¥1.51 Billion |
|
Jiugui Liquor Co Ltd
SHE:000799
|
China | CN¥1.07 Billion |
|
Bikaji Foods International Limited
NSE:BIKAJI
|
India | Rs5.32 Billion |
|
Shunsin Technology Holdings Ltd
TW:6451
|
Taiwan | NT$12.08 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Pharvaris BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PHVS company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharvaris BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharvaris BV (2017–2024)
The table below shows the annual total liabilities of Pharvaris BV from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $23.61 Million | +61.23% |
| 2023-12-31 | $14.65 Million | -20.72% |
| 2022-12-31 | $18.47 Million | +158.85% |
| 2021-12-31 | $7.14 Million | +34.31% |
| 2020-12-31 | $5.31 Million | +176.17% |
| 2019-12-31 | $1.92 Million | +299.74% |
| 2018-12-31 | $481.34K | +246.70% |
| 2017-12-31 | $138.84K | -- |
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more